EP1003500A4 - Apport intramural d'un activateur de monoxyde d'azote afin d'inhiber la formation de lesions apres blessure vasculaire - Google Patents

Apport intramural d'un activateur de monoxyde d'azote afin d'inhiber la formation de lesions apres blessure vasculaire

Info

Publication number
EP1003500A4
EP1003500A4 EP97938163A EP97938163A EP1003500A4 EP 1003500 A4 EP1003500 A4 EP 1003500A4 EP 97938163 A EP97938163 A EP 97938163A EP 97938163 A EP97938163 A EP 97938163A EP 1003500 A4 EP1003500 A4 EP 1003500A4
Authority
EP
European Patent Office
Prior art keywords
nitrogen monoxide
vascular injury
intramural administration
lesions
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97938163A
Other languages
German (de)
English (en)
Other versions
EP1003500A1 (fr
Inventor
John P Cooke
Sverin Schwarzacher
Tai T Lim
Alan C Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/695,792 external-priority patent/US5852058A/en
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of EP1003500A1 publication Critical patent/EP1003500A1/fr
Publication of EP1003500A4 publication Critical patent/EP1003500A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97938163A 1996-08-12 1997-08-07 Apport intramural d'un activateur de monoxyde d'azote afin d'inhiber la formation de lesions apres blessure vasculaire Withdrawn EP1003500A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US695792 1996-08-12
US08/695,792 US5852058A (en) 1993-06-11 1996-08-12 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
PCT/US1997/013905 WO1998006389A1 (fr) 1996-08-12 1997-08-07 Apport intramural d'un activateur de monoxyde d'azote afin d'inhiber la formation de lesions apres blessure vasculaire

Publications (2)

Publication Number Publication Date
EP1003500A1 EP1003500A1 (fr) 2000-05-31
EP1003500A4 true EP1003500A4 (fr) 2004-06-23

Family

ID=24794481

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97938163A Withdrawn EP1003500A4 (fr) 1996-08-12 1997-08-07 Apport intramural d'un activateur de monoxyde d'azote afin d'inhiber la formation de lesions apres blessure vasculaire

Country Status (4)

Country Link
EP (1) EP1003500A4 (fr)
JP (1) JP2000516612A (fr)
DE (1) DE69637676D1 (fr)
WO (1) WO1998006389A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6587718B2 (en) 1999-10-08 2003-07-01 Scimed Life Systems, Inc. Iontophoretic delivery to heart tissue
US6706274B2 (en) 2001-01-18 2004-03-16 Scimed Life Systems, Inc. Differential delivery of nitric oxide
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
EP1888510A4 (fr) 2005-05-27 2013-01-16 Univ North Carolina Particules liberant de l'oxyde nitrique pour therapie a base d'oxyde nitrique et applications biomedicales
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
WO2011022652A1 (fr) 2009-08-21 2011-02-24 Novan, Inc. Gels topiques
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0483614A1 (fr) * 1990-10-30 1992-05-06 Clintec Nutrition Company Utilisation des amino acides pour la protection et le rétablissement métabolique du tissu cardiaque ischémique
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
WO1995005866A1 (fr) * 1993-08-27 1995-03-02 Cortrak Medical Inc. Angioplastie et adminstration de medicament simultanees
WO1995024898A1 (fr) * 1994-03-17 1995-09-21 Comedicus, Incorporated Complexes formes par l'oxyde nitrique et des amines cardio-vasculaires et utilises comme agents cardio-vasculaires a double activite
WO1996000112A1 (fr) * 1994-06-23 1996-01-04 Cormedics Corp. Procede et appareil de traitement vasculaire
WO1997016983A1 (fr) * 1995-11-09 1997-05-15 The Board Of Trustees Of The Leland Stanford Junior University Amelioration de la fonction vasculaire par modulation de la production ou de l'activite de l'oxyde nitrique endogene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236413B1 (en) * 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
US5499971A (en) * 1990-06-15 1996-03-19 Cortrak Medical, Inc. Method for iontophoretically delivering drug adjacent to a heart
US5428070A (en) * 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0483614A1 (fr) * 1990-10-30 1992-05-06 Clintec Nutrition Company Utilisation des amino acides pour la protection et le rétablissement métabolique du tissu cardiaque ischémique
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
WO1995005866A1 (fr) * 1993-08-27 1995-03-02 Cortrak Medical Inc. Angioplastie et adminstration de medicament simultanees
WO1995024898A1 (fr) * 1994-03-17 1995-09-21 Comedicus, Incorporated Complexes formes par l'oxyde nitrique et des amines cardio-vasculaires et utilises comme agents cardio-vasculaires a double activite
WO1996000112A1 (fr) * 1994-06-23 1996-01-04 Cormedics Corp. Procede et appareil de traitement vasculaire
WO1997016983A1 (fr) * 1995-11-09 1997-05-15 The Board Of Trustees Of The Leland Stanford Junior University Amelioration de la fonction vasculaire par modulation de la production ou de l'activite de l'oxyde nitrique endogene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9806389A1 *

Also Published As

Publication number Publication date
JP2000516612A (ja) 2000-12-12
WO1998006389A1 (fr) 1998-02-19
DE69637676D1 (de) 2008-10-23
EP1003500A1 (fr) 2000-05-31

Similar Documents

Publication Publication Date Title
EP1003500A4 (fr) Apport intramural d'un activateur de monoxyde d'azote afin d'inhiber la formation de lesions apres blessure vasculaire
EP0295721A3 (en) Promotion of healing of meniscal tissue
DE59707228D1 (de) Verfahren zur nichtinvasiven bestimmung der sauerstoffsättigung in durchblutetem gewebe
DE69708880D1 (de) Verfahren zur direkten oxidation von olefinen zu olefinoxiden
HU9300776D0 (en) Carboxylic acid esters of rapamycine
DE69730054D1 (de) Verfahren zur Bestimmung von Stickoxyd
FR2612939B1 (fr) Equivalent de peau
IT1204696B (it) Procedimento e dispositivo per produrre due filoni continui di sigarette
GB8618933D0 (en) D c to d c converter
DE69325230D1 (de) Vorhof-Defibrillator zur verbesserten Erkennung von Vorhof-Signalen
JPS6416783A (en) Bridged diazabicycloalkylquinolinecarboxylic acid and esters of same
DE69313407D1 (de) Verfahren zur Verbesserung der Schalenpigmentation von Äpfeln
FI935168A7 (fi) 4-kloori-2-tiofeenikarboksyylihapon regioselektiivinen synteesi
GB2257971B (en) Isoquinoline diones and analogues thereof useful as intermediates
GB8707005D0 (en) Direct carbonylation of hydrocarbons
ZA883744B (en) Promotion of healing of meniscal tissue
MX173764B (es) Ureasa acida y procedimiento para producirla
IT1226586B (it) Composizioni farmaceutiche che favoriscono la cicatrizzazione di ferite e procedimento per prepararle
GB9611180D0 (en) Treatment of vascular lesions
PL292716A1 (en) Catalytic compositions and method of obtaining polymers
IT1231889B (it) Dispositivo per congiungere ed intrecciare nastri fibrosi
IT1197804B (it) Procedimento per preparare acidi eteroaril ed arilalcanoici
DE59010296D1 (de) Polyethercarbonsäureester und ihre Herstellung
EP0412573A3 (en) Analog signal to frequency converter
GB8718307D0 (en) Carbonylation of alkenes to ketones

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040507

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61N 1/30 B

Ipc: 7A 61M 29/02 B

Ipc: 7A 61M 25/10 B

Ipc: 7A 61K 31/195 A

17Q First examination report despatched

Effective date: 20061219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090408